Table 1 Univariate and Multivariate analysis to identify significant clinical factors for MLM
Clinical Characteristics | Non-MLM Group (n = 60) | MLM Group (n = 52) | univariate analysis | multivariate analysis | ||
|---|---|---|---|---|---|---|
Statistics | p-value | OR (95% CI) | p-value | |||
Age (mean ± SD, years) | 56.12 ± 9.84 | 57.96 ± 10.10 | −0.978 | 0.330 |  |  |
Sex | Â | Â | 4.125 | 0.042* | Â | Â |
 Male | 34 (30.4%) | 39 (34.8%) |  |  |  |  |
 Female | 26 (23.2%) | 13 (11.6%) |  |  |  |  |
pT stage |  |  | 7.328 | 0.026* | 2.464 (1.252–4.851) | 0.009* |
 pT2 | 14 (12.5%) | 5 (4.4%) |  |  |  |  |
 pT3 | 39 (34.8%) | 32 (28.6%) |  |  |  |  |
 pT4 | 7 (6.3%) | 15 (13.4%) |  |  |  |  |
pN stage | Â | Â | 2.441 | 0.295 | Â | Â |
 pN0 | 8 (7.1%) | 5 (4.5%) |  |  |  |  |
 pN1 | 35 (31.3%) | 25 (22.3%) |  |  |  |  |
 pN2 | 17 (15.2%) | 22 (19.6%) |  |  |  |  |
Hepatitis | Â | Â | 1.876 | 0.171 | Â | Â |
 Negative | 41 (36.6%) | 29 (25.9%) |  |  |  |  |
 Positive | 19 (17.0%) | 23 (20.5%) |  |  |  |  |
CEA | Â | Â | 4.633 | 0.031* | Â | Â |
 Normal (< 5 ng/ml) | 43 (38.4%) | 27 (24.1%) |  |  |  |  |
 Elevated (≥5 ng/ml) | 17 (15.2%) | 25 (22.3%) |  |  |  |  |
CA19–9 |  |  | 1.450 | 0.229 |  |  |
 Normal (< 37 U/ml) | 51 (45.5%) | 48 (42.9%) |  |  |  |  |
 Elevated (≥37 U/ml) | 9 (8.0%) | 4 (3.6%) |  |  |  |  |